Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Details

Connection

Lisa Bero to Humans

This is a "connection" page, showing publications Lisa Bero has written about Humans.

 
Connection Strength
  
 
 
2.428
  
  1. Traeger AC, Bero LA. Corporate Influences on Science and Health-the Case of Spinal Cord Stimulation. JAMA Intern Med. 2024 Feb 01; 184(2):129-130.
    View in: PubMed
    Score: 0.026
  2. Toews I, Anglemyer A, Nyirenda JL, Alsaid D, Balduzzi S, Grummich K, Schwingshackl L, Bero L. Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials: a meta-epidemiological study. Cochrane Database Syst Rev. 2024 01 04; 1:MR000034.
    View in: PubMed
    Score: 0.026
  3. Bero L, Lawrence R, Oberste JP, Li T, Leslie L, Rittiphairoj T, Piper C, Wang GS, Brooks-Russell A, Yim TW, Tung G, Samet JM. Health Effects of High-Concentration Cannabis Products: Scoping Review and Evidence Map. Am J Public Health. 2023 12; 113(12):1332-1342.
    View in: PubMed
    Score: 0.025
  4. Chiu K, Thow AM, Bero L. Understanding the Dynamics of More Restrictive Medicines Policy: A Case Study of Codeine Up-Scheduling in Australia. Int J Health Policy Manag. 2023; 12:6872.
    View in: PubMed
    Score: 0.024
  5. Parker L, Bero L. Managing risk from conflicts of interest in guideline development committees. BMJ. 2022 12 06; 379:e072252.
    View in: PubMed
    Score: 0.024
  6. Chiu K, Thow AM, Bero L. The tension between national consistency and jurisdictional professional expansion: The case of pharmacist-administered vaccinations. Res Social Adm Pharm. 2022 10; 18(10):3782-3791.
    View in: PubMed
    Score: 0.023
  7. Chiu K, Thow AM, Bero L. "Never waste a good crisis": Opportunities and constraints from the COVID-19 pandemic on pharmacists' scope of practice. Res Social Adm Pharm. 2022 09; 18(9):3638-3648.
    View in: PubMed
    Score: 0.023
  8. Hilton Boon M, Burns J, Craig P, Griebler U, Heise TL, Vittal Katikireddi S, Rehfuess E, Shepperd S, Thomson H, Bero L. Value and Challenges of Using Observational Studies in Systematic Reviews of Public Health Interventions. Am J Public Health. 2022 04; 112(4):548-552.
    View in: PubMed
    Score: 0.023
  9. Mintzes B, Bhasale A, Torka M, Lopert R, Pearson SA, Lexchin J, Bero L. A sorry tale of unnecessary secrecy about medicine safety. Intern Med J. 2021 Oct; 51(10):1765-1766.
    View in: PubMed
    Score: 0.022
  10. Karanges EA, Nangla C, Parker L, Fabbri A, Farquhar C, Bero L. Pharmaceutical industry payments and assisted reproduction in Australia: a retrospective observational study. BMJ Open. 2021 08 31; 11(9):e049710.
    View in: PubMed
    Score: 0.022
  11. Bero L, Lawrence R, Leslie L, Chiu K, McDonald S, Page MJ, Grundy Q, Parker L, Boughton S, Kirkham JJ, Featherstone R. Cross-sectional study of preprints and final journal publications from COVID-19 studies: discrepancies in results reporting and spin in interpretation. BMJ Open. 2021 07 16; 11(7):e051821.
    View in: PubMed
    Score: 0.021
  12. Dai Z, McKenzie JE, McDonald S, Baram L, Page MJ, Allman-Farinelli M, Raubenheimer D, Bero LA. Assessment of the Methods Used to Develop Vitamin D and Calcium Recommendations-A Systematic Review of Bone Health Guidelines. Nutrients. 2021 Jul 15; 13(7).
    View in: PubMed
    Score: 0.021
  13. Boughton SL, Wilkinson J, Bero L. When beauty is but skin deep: dealing with problematic studies in systematic reviews. Cochrane Database Syst Rev. 2021 06 03; 6:ED000152.
    View in: PubMed
    Score: 0.021
  14. Verbeek J, Hoving J, Boschman J, Chong LY, Livingstone-Banks J, Bero L. Systematic Reviews Should Consider Effects From Both the Population and the Individual Perspective. Am J Public Health. 2021 05; 111(5):820-825.
    View in: PubMed
    Score: 0.021
  15. Parker L, Grundy Q, Fabbri A, Mintzes B, Bero L. 'Lines in the sand': an Australian qualitative study of patient group practices to promote independence from pharmaceutical industry funders. BMJ Open. 2021 02 09; 11(2):e045140.
    View in: PubMed
    Score: 0.021
  16. Chartres N, Fabbri A, McDonald S, Diong J, McKenzie JE, Bero L. Association of food industry ties with findings of studies examining the effect of dairy food intake on cardiovascular disease and mortality: systematic review and meta-analysis. BMJ Open. 2020 12 04; 10(12):e039036.
    View in: PubMed
    Score: 0.021
  17. Parker L, Bennett A, Mintzes B, Grundy Q, Fabbri A, Karanges EA, Bero L. "There are ways ? drug companies will get into DTC decisions": How Australian drug and therapeutics committees address pharmaceutical industry influence. Br J Clin Pharmacol. 2021 05; 87(5):2341-2353.
    View in: PubMed
    Score: 0.021
  18. Wang Z, Grundy Q, Parker L, Bero L. Variations in processes for guideline adaptation: a qualitative study of World Health Organization staff experiences in implementing guidelines. BMC Public Health. 2020 Nov 23; 20(1):1758.
    View in: PubMed
    Score: 0.021
  19. Bero LA. Improving the Quality of Systematic Reviews in Public Health: Introduction to the Series. Am J Public Health. 2020 11; 110(11):1601-1602.
    View in: PubMed
    Score: 0.020
  20. Anglemyer A, Moore TH, Parker L, Chambers T, Grady A, Chiu K, Parry M, Wilczynska M, Flemyng E, Bero L. Digital contact tracing technologies in epidemics: a rapid review. Cochrane Database Syst Rev. 2020 08 18; 8:CD013699.
    View in: PubMed
    Score: 0.020
  21. Chartres N, Grundy Q, Parker LM, Bero LA. "It's Not Smooth Sailing": Bridging the Gap Between Methods and Content Expertise in Public Health Guideline Development. Int J Health Policy Manag. 2020 08 01; 9(8):335-343.
    View in: PubMed
    Score: 0.020
  22. Dai Z, Kroeger CM, Lawrence M, Scrinis G, Bero L. Comparison of methodological quality between the 2007 and 2019 Canadian dietary guidelines. Public Health Nutr. 2020 11; 23(16):2879-2885.
    View in: PubMed
    Score: 0.020
  23. Moynihan R, Albarqouni L, Nangla C, Dunn AG, Lexchin J, Bero L. Financial ties between leaders of influential US professional medical associations and industry: cross sectional study. BMJ. 2020 05 27; 369:m1505.
    View in: PubMed
    Score: 0.020
  24. Bero LA. Producing Independent, Systematic Review Evidence: Cochrane's Response to COVID-19. Am J Public Health. 2020 07; 110(7):952-953.
    View in: PubMed
    Score: 0.020
  25. Moynihan R, Fabbri A, Parker L, Bero L. Mixed methods evaluation of workshops for citizen health advocates about financial conflicts of interests in healthcare. BMJ Open. 2020 05 10; 10(5):e034195.
    View in: PubMed
    Score: 0.020
  26. Chiu K, McDonald S, Legg T, Karanges EA, Bero L. Policies affecting the supply and access of opioid analgesics: a scoping review protocol. JBI Evid Synth. 2020 05; 18(5):1124-1134.
    View in: PubMed
    Score: 0.020
  27. Grundy Q, Mazzarello S, Bero L. A comparison of policy provisions for managing "financial" and "non-financial" interests across health-related research organizations: A qualitative content analysis. Account Res. 2020 05; 27(4):212-237.
    View in: PubMed
    Score: 0.020
  28. Grundy Q, Dunn AG, Bero L. Improving researchers' conflict of interest declarations. BMJ. 2020 Mar 11; 368:m422.
    View in: PubMed
    Score: 0.020
  29. Karanges EA, Ting N, Parker L, Fabbri A, Bero L. Pharmaceutical industry payments to leaders of professional medical associations in Australia: Focus on cardiovascular disease and diabetes. Aust J Gen Pract. 2020 03; 49(3):151-154.
    View in: PubMed
    Score: 0.020
  30. Ding D, Nguyen B, Gebel K, Bauman A, Bero L. Duplicate and salami publication: a prevalence study of journal policies. Int J Epidemiol. 2020 02 01; 49(1):281-288.
    View in: PubMed
    Score: 0.019
  31. Grundy Q, Mayes C, Holloway K, Mazzarello S, Thombs BD, Bero L. Conflict of interest as ethical shorthand: understanding the range and nature of "non-financial conflict of interest" in biomedicine. J Clin Epidemiol. 2020 04; 120:1-7.
    View in: PubMed
    Score: 0.019
  32. Bero L, Chiu K, Grundy Q. The SSSPIN study-spin in studies of spin: meta-research analysis. BMJ. 2019 Dec 18; 367:l6202.
    View in: PubMed
    Score: 0.019
  33. Parker L, Fabbri A, Grundy Q, Mintzes B, Bero L. "Asset exchange"-interactions between patient groups and pharmaceutical industry: Australian qualitative study. BMJ. 2019 12 12; 367:l6694.
    View in: PubMed
    Score: 0.019
  34. Bero L, Hr?bjartsson A, Grundy Q. Response to Soares et al. Eur J Clin Nutr. 2020 02; 74(2):351-352.
    View in: PubMed
    Score: 0.019
  35. Wang Z, Grundy Q, Parker L, Bero L. Health promoter, advocate, legitimiser - the many roles of WHO guidelines: a qualitative study. Health Res Policy Syst. 2019 Dec 05; 17(1):96.
    View in: PubMed
    Score: 0.019
  36. Grundy Q, Chiu K, Bero L. Commercialization of User Data by Developers of Medicines-Related Apps: a Content Analysis. J Gen Intern Med. 2019 12; 34(12):2833-2841.
    View in: PubMed
    Score: 0.019
  37. Dai Z, Kroeger CM, McDonald S, Page MJ, McKenzie JE, Allman-Farinelli M, Raubenheimer D, Bero L. Methodological quality of public health guideline recommendations on vitamin D and calcium : a systematic review protocol. BMJ Open. 2019 11 07; 9(11):e031840.
    View in: PubMed
    Score: 0.019
  38. McDonald S, Fabbri A, Parker L, Williams J, Bero L. Medical donations are not always free: an assessment of compliance of medicine and medical device donations with World Health Organization guidelines (2009-2017). Int Health. 2019 09 02; 11(5):379-402.
    View in: PubMed
    Score: 0.019
  39. Behdarvand B, Karanges EA, Bero L. Pharmaceutical industry funding of events for healthcare professionals on non-vitamin K oral anticoagulants in Australia: an observational study. BMJ Open. 2019 08 20; 9(8):e030253.
    View in: PubMed
    Score: 0.019
  40. Chartres N, Fabbri A, McDonald S, Turton J, Allman-Farinelli M, McKenzie J, Bero L. Association of industry ties with outcomes of studies examining the effect of wholegrain foods on cardiovascular disease and mortality: systematic review and meta-analysis. BMJ Open. 2019 05 19; 9(5):e022912.
    View in: PubMed
    Score: 0.019
  41. Bero LA, Norris SL, Lawrence MA. Making nutrition guidelines fit for purpose. BMJ. 2019 Apr 16; 365:l1579.
    View in: PubMed
    Score: 0.018
  42. Parker L, Karanges EA, Bero L. Changes in the type and amount of spending disclosed by Australian pharmaceutical companies: an observational study. BMJ Open. 2019 02 19; 9(2):e024928.
    View in: PubMed
    Score: 0.018
  43. Moynihan R, Lai A, Jarvis H, Duggan G, Goodrick S, Beller E, Bero L. Undisclosed financial ties between guideline writers and pharmaceutical companies: a cross-sectional study across 10 disease categories. BMJ Open. 2019 02 05; 9(2):e025864.
    View in: PubMed
    Score: 0.018
  44. Fabbri A, Holland TJ, Bero LA. Food industry sponsorship of academic research: investigating commercial bias in the research agenda. Public Health Nutr. 2018 12; 21(18):3422-3430.
    View in: PubMed
    Score: 0.018
  45. de Rezende LFM, Rey-L?pez JP, de S? TH, Chartres N, Fabbri A, Powell L, Stamatakis E, Bero L. Reporting bias in the literature on the associations of health-related behaviors and statins with cardiovascular disease and all-cause mortality. PLoS Biol. 2018 06; 16(6):e2005761.
    View in: PubMed
    Score: 0.017
  46. Parker L, Grundy Q, Bero L. Interpreting evidence in general practice: Bias and conflicts of interest. Aust J Gen Pract. 2018 06; 47(6):337-340.
    View in: PubMed
    Score: 0.017
  47. Wang Z, Norris SL, Bero L. The advantages and limitations of guideline adaptation frameworks. Implement Sci. 2018 05 29; 13(1):72.
    View in: PubMed
    Score: 0.017
  48. Parker L, Williams J, Bero L. Ethical drug marketing criteria for the 21st century. BMJ. 2018 Apr 30; 361:k1809.
    View in: PubMed
    Score: 0.017
  49. Bero L. Meta-research matters: Meta-spin cycles, the blindness of bias, and rebuilding trust. PLoS Biol. 2018 04; 16(4):e2005972.
    View in: PubMed
    Score: 0.017
  50. Blake P, Dur?o S, Naude CE, Bero L. An analysis of methods used to synthesize evidence and grade recommendations in food-based dietary guidelines. Nutr Rev. 2018 04 01; 76(4):290-300.
    View in: PubMed
    Score: 0.017
  51. Mintzes B, Swandari S, Fabbri A, Grundy Q, Moynihan R, Bero L. Does industry-sponsored education foster overdiagnosis and overtreatment of depression, osteoporosis and over-active bladder syndrome? An Australian cohort study. BMJ Open. 2018 02 13; 8(2):e019027.
    View in: PubMed
    Score: 0.017
  52. Bero L. Developing reliable dietary guidelines. BMJ. 2017 11 03; 359:j4845.
    View in: PubMed
    Score: 0.017
  53. Grundy Q, Held F, Bero L. A Social Network Analysis of the Financial Links Backing Health and Fitness Apps. Am J Public Health. 2017 11; 107(11):1783-1788.
    View in: PubMed
    Score: 0.016
  54. Fabbri A, Chartres N, Bero LA. Study sponsorship and the nutrition research agenda: analysis of cohort studies examining the association between nutrition and obesity. Public Health Nutr. 2017 Dec; 20(17):3193-3199.
    View in: PubMed
    Score: 0.016
  55. Fabbri A, Grundy Q, Mintzes B, Swandari S, Moynihan R, Walkom E, Bero LA. A cross-sectional analysis of pharmaceutical industry-funded events for health professionals in Australia. BMJ Open. 2017 06 30; 7(6):e016701.
    View in: PubMed
    Score: 0.016
  56. Grundy Q, Held FP, Bero LA. Tracing the Potential Flow of Consumer Data: A Network Analysis of Prominent Health and Fitness Apps. J Med Internet Res. 2017 06 28; 19(6):e233.
    View in: PubMed
    Score: 0.016
  57. Cosgrove L, Shaughnessy AF, Peters SM, Lexchin JR, Bursztajn H, Bero L. Conflicts of Interest and the Presence of Methodologists on Guideline Development Panels: A Cross-Sectional Study of Clinical Practice Guidelines for Major Depressive Disorder. Psychother Psychosom. 2017; 86(3):168-170.
    View in: PubMed
    Score: 0.016
  58. Moynihan R, Bero L. Toward a Healthier Patient Voice: More Independence, Less Industry Funding. JAMA Intern Med. 2017 03 01; 177(3):350-351.
    View in: PubMed
    Score: 0.016
  59. Apollonio DE, Bero LA. Interpretation and use of evidence in state policymaking: a qualitative analysis. BMJ Open. 2017 02 20; 7(2):e012738.
    View in: PubMed
    Score: 0.016
  60. Lundh A, Bero L. The ties that bind. BMJ. 2017 Jan 17; 356:j176.
    View in: PubMed
    Score: 0.016
  61. Fabbri A, Chartres N, Scrinis G, Bero LA. Study sponsorship and the nutrition research agenda: analysis of randomized controlled trials included in systematic reviews of nutrition interventions to address obesity. Public Health Nutr. 2017 May; 20(7):1306-1313.
    View in: PubMed
    Score: 0.016
  62. Chartres N, Fabbri A, Bero LA. Association of Industry Sponsorship With Outcomes of Nutrition Studies: A Systematic Review and Meta-analysis. JAMA Intern Med. 2016 Dec 01; 176(12):1769-1777.
    View in: PubMed
    Score: 0.016
  63. Apollonio D, Philipps R, Bero L. Interventions for tobacco use cessation in people in treatment for or recovery from substance use disorders. Cochrane Database Syst Rev. 2016 11 23; 11:CD010274.
    View in: PubMed
    Score: 0.016
  64. Bero L. Systematic Review: A Method at Risk for Being Corrupted. Am J Public Health. 2017 Jan; 107(1):93-96.
    View in: PubMed
    Score: 0.016
  65. Grundy Q, Fabbri A, Mintzes B, Swandari S, Bero L. The Inclusion of Nurses in Pharmaceutical Industry-Sponsored Events: Guess Who Is Also Coming to Dinner? JAMA Intern Med. 2016 11 01; 176(11):1718-1720.
    View in: PubMed
    Score: 0.016
  66. Norris SL, Bero L. GRADE Methods for Guideline Development: Time to Evolve? Ann Intern Med. 2016 Dec 06; 165(11):810-811.
    View in: PubMed
    Score: 0.015
  67. Mandrioli D, Kearns CE, Bero LA. Relationship between Research Outcomes and Risk of Bias, Study Sponsorship, and Author Financial Conflicts of Interest in Reviews of the Effects of Artificially Sweetened Beverages on Weight Outcomes: A Systematic Review of Reviews. PLoS One. 2016; 11(9):e0162198.
    View in: PubMed
    Score: 0.015
  68. Apollonio DE, Wolfe N, Bero LA. Realist review of policy intervention studies aimed at reducing exposures to environmental hazards in the United States. BMC Public Health. 2016 08 18; 16(1):822.
    View in: PubMed
    Score: 0.015
  69. Wang Z, Norris SL, Bero L. Implementation plans included in World Health Organisation guidelines. Implement Sci. 2016 05 20; 11(1):76.
    View in: PubMed
    Score: 0.015
  70. Bero L, Anglemyer A, Vesterinen H, Krauth D. The relationship between study sponsorship, risks of bias, and research outcomes in atrazine exposure studies conducted in non-human animals: Systematic review and meta-analysis. Environ Int. 2016 Jul-Aug; 92-93:597-604.
    View in: PubMed
    Score: 0.015
  71. Tuller D, Bero L. Big Tobacco and Drugstore Chains: A Long, Cozy Relationship. JAMA Oncol. 2015 Dec; 1(9):1215-6.
    View in: PubMed
    Score: 0.015
  72. Bero L. Bias related to funding source in statin trials. BMJ. 2014 Oct 03; 349:g5949.
    View in: PubMed
    Score: 0.013
  73. Fox DM, Bero L. Systematic reviews: perhaps "the answer to policy makers' prayers"? Environ Health Perspect. 2014 Oct; 122(10):A262-3.
    View in: PubMed
    Score: 0.013
  74. Magrini N, Robertson J, de Joncheere K, Bero L. On WHO's essential medicines process and transparency. BMJ. 2014 Sep 17; 349:g5637.
    View in: PubMed
    Score: 0.013
  75. Formoso G, Marata AM, Magrini N, Bero L. A clearer view of evidence in treating macular degeneration: off-label policies and independent research. Cochrane Database Syst Rev. 2014 Sep 15; (9):ED000090.
    View in: PubMed
    Score: 0.013
  76. Schroll JB, Abdel-Sattar M, Bero L. The Food and Drug Administration reports provided more data but were more difficult to use than the European Medicines Agency reports. J Clin Epidemiol. 2015 Jan; 68(1):102-7.
    View in: PubMed
    Score: 0.013
  77. Bero L. What is in a name? Nonfinancial influences on the outcomes of systematic reviews and guidelines. J Clin Epidemiol. 2014 Nov; 67(11):1239-41.
    View in: PubMed
    Score: 0.013
  78. Anglemyer A, Horvath HT, Bero L. Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials. Cochrane Database Syst Rev. 2014 Apr 29; (4):MR000034.
    View in: PubMed
    Score: 0.013
  79. Krauth D, Anglemyer A, Philipps R, Bero L. Nonindustry-sponsored preclinical studies on statins yield greater efficacy estimates than industry-sponsored studies: a meta-analysis. PLoS Biol. 2014 Jan; 12(1):e1001770.
    View in: PubMed
    Score: 0.013
  80. Apollonio DE, Glantz SA, Bero LA. Term limits and the tobacco industry. Soc Sci Med. 2014 Mar; 104:1-5.
    View in: PubMed
    Score: 0.013
  81. Wolfe N, G?tzsche PC, Bero L. Strategies for obtaining unpublished drug trial data: a qualitative interview study. Syst Rev. 2013 May 16; 2:31.
    View in: PubMed
    Score: 0.012
  82. Nguyen NY, Bero L. Medicaid drug selection committees and inadequate management of conflicts of interest. JAMA Intern Med. 2013 Mar 11; 173(5):338-43.
    View in: PubMed
    Score: 0.012
  83. Pande S, Hiller JE, Nkansah N, Bero L. The effect of pharmacist-provided non-dispensing services on patient outcomes, health service utilisation and costs in low- and middle-income countries. Cochrane Database Syst Rev. 2013 Feb 28; (2):CD010398.
    View in: PubMed
    Score: 0.012
  84. Odierna DH, Forsyth SR, White J, Bero LA. The cycle of bias in health research: a framework and toolbox for critical appraisal training. Account Res. 2013; 20(2):127-41.
    View in: PubMed
    Score: 0.012
  85. Odierna DH, White J, Forsyth S, Bero LA. Critical appraisal training increases understanding and confidence and enhances the use of evidence in diverse categories of learners. Health Expect. 2015 Apr; 18(2):273-87.
    View in: PubMed
    Score: 0.012
  86. Taba P, Rosenthal M, Habicht J, Tarien H, Mathiesen M, Hill S, Bero L. Barriers and facilitators to the implementation of clinical practice guidelines: a cross-sectional survey among physicians in Estonia. BMC Health Serv Res. 2012 Dec 13; 12:455.
    View in: PubMed
    Score: 0.012
  87. Bero LA, Hill S, Habicht J, Mathiesen M, Starkopf J. The updated clinical guideline development process in Estonia is an efficient method for developing evidence-based guidelines. J Clin Epidemiol. 2013 Feb; 66(2):132-9.
    View in: PubMed
    Score: 0.012
  88. Bero LA, Binder L. The Cochrane Collaboration review prioritization projects show that a variety of approaches successfully identify high-priority topics. J Clin Epidemiol. 2013 May; 66(5):472-3.
    View in: PubMed
    Score: 0.012
  89. Anson A, Ramay B, de Esparza AR, Bero L. Availability, prices and affordability of the World Health Organization's essential medicines for children in Guatemala. Global Health. 2012 Jul 02; 8:22.
    View in: PubMed
    Score: 0.011
  90. Hill S, Yang A, Bero L. Priority medicines for maternal and child health: a global survey of national essential medicines lists. PLoS One. 2012; 7(5):e38055.
    View in: PubMed
    Score: 0.011
  91. Malone RE, Grundy Q, Bero LA. Tobacco industry denormalisation as a tobacco control intervention: a review. Tob Control. 2012 Mar; 21(2):162-70.
    View in: PubMed
    Score: 0.011
  92. Sutton P, Woodruff TJ, Vogel S, Bero LA. Conrad and Becker's "10 Criteria" fall short of addressing conflicts of interest in chemical safety studies. Environ Health Perspect. 2011 Dec; 119(12):A506-7; author reply A508-9.
    View in: PubMed
    Score: 0.011
  93. Walleser S, Hill SR, Bero LA. Characteristics and quality of reporting of cluster randomized trials in children: reporting needs improvement. J Clin Epidemiol. 2011 Dec; 64(12):1331-40.
    View in: PubMed
    Score: 0.011
  94. Krle?a-Jeri? K, Lemmens T, Reveiz L, Cuervo LG, Bero LA. Prospective registration and results disclosure of clinical trials in the Americas: a roadmap toward transparency. Rev Panam Salud Publica. 2011 Jul; 30(1):87-96.
    View in: PubMed
    Score: 0.011
  95. Millar TP, Wong S, Odierna DH, Bero LA. Applying the essential medicines concept to US preferred drug lists. Am J Public Health. 2011 Aug; 101(8):1444-8.
    View in: PubMed
    Score: 0.011
  96. Saint-Raymond A, Hill S, Martines J, Bahl R, Fontaine O, Bero L. CONSORT 2010. Lancet. 2010 Jul 24; 376(9737):229-30.
    View in: PubMed
    Score: 0.010
  97. Nkansah N, Mostovetsky O, Yu C, Chheng T, Beney J, Bond CM, Bero L. Effect of outpatient pharmacists' non-dispensing roles on patient outcomes and prescribing patterns. Cochrane Database Syst Rev. 2010 Jul 07; (7):CD000336.
    View in: PubMed
    Score: 0.010
  98. Montini T, George A, Martin-Mollard M, Bero LA. The role of public participation in public health initiatives: an analysis of the WHO Framework Convention on Tobacco Control. Glob Public Health. 2010; 5(1):48-61.
    View in: PubMed
    Score: 0.010
  99. Rasmussen N, Lee K, Bero L. Association of trial registration with the results and conclusions of published trials of new oncology drugs. Trials. 2009 Dec 16; 10:116.
    View in: PubMed
    Score: 0.010
  100. Cook DM, Bero LA. The politics of smoking in federal buildings: an executive order case study. Am J Public Health. 2009 Sep; 99(9):1588-95.
    View in: PubMed
    Score: 0.009
  101. Apollonio DE, Bero LA. Evidence and argument in policymaking: development of workplace smoking legislation. BMC Public Health. 2009 Jun 17; 9:189.
    View in: PubMed
    Score: 0.009
  102. Rattinger G, Bero L. Factors associated with results and conclusions of trials of thiazolidinediones. PLoS One. 2009 Jun 08; 4(6):e5826.
    View in: PubMed
    Score: 0.009
  103. Odierna DH, Bero LA. Systematic reviews reveal unrepresentative evidence for the development of drug formularies for poor and nonwhite populations. J Clin Epidemiol. 2009 Dec; 62(12):1268-78.
    View in: PubMed
    Score: 0.009
  104. Nkansah N, Nguyen T, Iraninezhad H, Bero L. Randomized trials assessing calcium supplementation in healthy children: relationship between industry sponsorship and study outcomes. Public Health Nutr. 2009 Oct; 12(10):1931-7.
    View in: PubMed
    Score: 0.009
  105. Kummerfeldt CE, Barnoya J, Bero L. Philip Morris involvement in the development of an air quality laboratory in El Salvador. Tob Control. 2009 Jun; 18(3):241-4.
    View in: PubMed
    Score: 0.009
  106. White J, Bandura A, Bero LA. Moral disengagement in the corporate world. Account Res. 2009 Jan-Mar; 16(1):41-74.
    View in: PubMed
    Score: 0.009
  107. Cook DM, Gurugubelli RK, Bero LA. Risk management policy and black-box warnings: a qualitative analysis of US FDA proceedings. Drug Saf. 2009; 32(11):1057-66.
    View in: PubMed
    Score: 0.009
  108. Montini T, Bero LA. Implementation of a workplace smoking ban in bars: the limits of local discretion. BMC Public Health. 2008 Dec 08; 8:402.
    View in: PubMed
    Score: 0.009
  109. Rising K, Bacchetti P, Bero L. Reporting bias in drug trials submitted to the Food and Drug Administration: review of publication and presentation. PLoS Med. 2008 Nov 25; 5(11):e217; discussion e217.
    View in: PubMed
    Score: 0.009
  110. Bero L. "Experimental" institutional models for corporate funding of academic research: unknown effects on the research enterprise. J Clin Epidemiol. 2008 Jul; 61(7):629-33.
    View in: PubMed
    Score: 0.009
  111. Jewell CJ, Bero LA. "Developing good taste in evidence": facilitators of and hindrances to evidence-informed health policymaking in state government. Milbank Q. 2008 Jun; 86(2):177-208.
    View in: PubMed
    Score: 0.009
  112. Finley PR, Bero L. Clarification of study and citation. Arch Intern Med. 2007 Dec 10; 167(22):2531; author reply 2531-2.
    View in: PubMed
    Score: 0.008
  113. Yank V, Rennie D, Bero LA. Financial ties and concordance between results and conclusions in meta-analyses: retrospective cohort study. BMJ. 2007 Dec 08; 335(7631):1202-5.
    View in: PubMed
    Score: 0.008
  114. Boyd EA, Bero LA. Defining financial conflicts and managing research relationships: an analysis of university conflict of interest committee decisions. Sci Eng Ethics. 2007 Dec; 13(4):415-35.
    View in: PubMed
    Score: 0.008
  115. Prochaska JJ, Hall SM, Bero LA. Tobacco use among individuals with schizophrenia: what role has the tobacco industry played? Schizophr Bull. 2008 May; 34(3):555-67.
    View in: PubMed
    Score: 0.008
  116. White J, Parascandola M, Bero L. Tobacco industry research and protection of human subjects: a case study of R. J. Reynolds. Nicotine Tob Res. 2007 Nov; 9(11):1213-25.
    View in: PubMed
    Score: 0.008
  117. Freemantle N, Harvey EL, Wolf F, Grimshaw JM, Grilli R, Bero LA. WITHDRAWN: Printed educational materials: effects on professional practice and health care outcomes. Cochrane Database Syst Rev. 2007 Jul 18; (2):CD000172.
    View in: PubMed
    Score: 0.008
  118. Bero L. [Shall we ban industrial funds for research?]. Epidemiol Prev. 2007 Jul-Aug; 31(4):171-4.
    View in: PubMed
    Score: 0.008
  119. Bero L, Oostvogel F, Bacchetti P, Lee K. Factors associated with findings of published trials of drug-drug comparisons: why some statins appear more efficacious than others. PLoS Med. 2007 Jun; 4(6):e184.
    View in: PubMed
    Score: 0.008
  120. Steinman MA, Harper GM, Chren MM, Landefeld CS, Bero LA. Characteristics and impact of drug detailing for gabapentin. PLoS Med. 2007 Apr; 4(4):e134.
    View in: PubMed
    Score: 0.008
  121. Apollonio DE, Bero LA. The creation of industry front groups: the tobacco industry and "get government off our back". Am J Public Health. 2007 Mar; 97(3):419-27.
    View in: PubMed
    Score: 0.008
  122. Lopipero P, Bero LA. Tobacco interests or the public interest: 20 years of industry strategies to undermine airline smoking restrictions. Tob Control. 2006 Aug; 15(4):323-32.
    View in: PubMed
    Score: 0.008
  123. Nguyen NT, Cook DM, Bero LA. The decision-making process of US Food and Drug Administration advisory committees on switches from prescription to over-the-counter status: a comparative case study. Clin Ther. 2006 Aug; 28(8):1231-1243.
    View in: PubMed
    Score: 0.008
  124. Lee KP, Boyd EA, Holroyd-Leduc JM, Bacchetti P, Bero LA. Predictors of publication: characteristics of submitted manuscripts associated with acceptance at major biomedical journals. Med J Aust. 2006 Jun 19; 184(12):621-6.
    View in: PubMed
    Score: 0.008
  125. Cook DM, Bero LA. Identifying carcinogens: the tobacco industry and regulatory politics in the United States. Int J Health Serv. 2006; 36(4):747-66.
    View in: PubMed
    Score: 0.007
  126. Glaser BE, Bero LA. Attitudes of academic and clinical researchers toward financial ties in research: a systematic review. Sci Eng Ethics. 2005 Oct; 11(4):553-73.
    View in: PubMed
    Score: 0.007
  127. Cook DM, Tong EK, Glantz SA, Bero LA. The power of paperwork: how Philip Morris neutralized the medical code for secondhand smoke. Health Aff (Millwood). 2005 Jul-Aug; 24(4):994-1004.
    View in: PubMed
    Score: 0.007
  128. Bero LA, Glantz S, Hong MK. The limits of competing interest disclosures. Tob Control. 2005 Apr; 14(2):118-26.
    View in: PubMed
    Score: 0.007
  129. Bero LA. Tobacco industry manipulation of research. Public Health Rep. 2005 Mar-Apr; 120(2):200-8.
    View in: PubMed
    Score: 0.007
  130. Baba A, Cook DM, McGarity TO, Bero LA. Legislating "sound science": the role of the tobacco industry. Am J Public Health. 2005; 95 Suppl 1:S20-7.
    View in: PubMed
    Score: 0.007
  131. Bero LA. Managing financial conflicts of interest in research. J Am Coll Dent. 2005; 72(2):4-9.
    View in: PubMed
    Score: 0.007
  132. Dunsby J, Bero L. A nicotine delivery device without the nicotine? Tobacco industry development of low nicotine cigarettes. Tob Control. 2004 Dec; 13(4):362-9.
    View in: PubMed
    Score: 0.007
  133. White J, Bero LA. Public health under attack: the American Stop Smoking Intervention Study (ASSIST) and the tobacco industry. Am J Public Health. 2004 Feb; 94(2):240-50.
    View in: PubMed
    Score: 0.006
  134. Page MJ, Sterne JAC, Boutron I, Hr?bjartsson A, Kirkham JJ, Li T, Lundh A, Mayo-Wilson E, McKenzie JE, Stewart LA, Sutton AJ, Bero L, Dunn AG, Dwan K, Elbers RG, Kanukula R, Meerpohl JJ, Turner EH, Higgins JPT. ROB-ME: a tool for assessing risk of bias due to missing evidence in systematic reviews with meta-analysis. BMJ. 2023 11 20; 383:e076754.
    View in: PubMed
    Score: 0.006
  135. Langford AV, Bero L, Lin CC, Blyth FM, Doctor JN, Holliday S, Jeon YH, Moullin JC, Murnion B, Nielsen S, Penm J, Reeve E, Reid S, Wale J, Osman R, Gnjidic D, Schneider CR. Context matters: using an Evidence to Decision (EtD) framework to develop and encourage uptake of opioid deprescribing guideline recommendations at the point-of-care. J Clin Epidemiol. 2024 Jan; 165:111204.
    View in: PubMed
    Score: 0.006
  136. Finley PR, Rens HR, Pont JT, Gess SL, Louie C, Bull SA, Lee JY, Bero LA. Impact of a collaborative care model on depression in a primary care setting: a randomized controlled trial. Pharmacotherapy. 2003 Sep; 23(9):1175-85.
    View in: PubMed
    Score: 0.006
  137. Malone RE, Bero LA. Chasing the dollar: why scientists should decline tobacco industry funding. J Epidemiol Community Health. 2003 Aug; 57(8):546-8.
    View in: PubMed
    Score: 0.006
  138. Boyd EA, Cho MK, Bero LA. Financial conflict-of-interest policies in clinical research: issues for clinical investigators. Acad Med. 2003 Aug; 78(8):769-74.
    View in: PubMed
    Score: 0.006
  139. Langford AV, Lin CC, Bero L, Blyth FM, Doctor J, Holliday S, Jeon YH, Moullin J, Murnion B, Nielsen S, Osman R, Penm J, Reeve E, Reid S, Wale J, Schneider CR, Gnjidic D. Clinical practice guideline for deprescribing opioid analgesics: summary of recommendations. Med J Aust. 2023 07 17; 219(2):80-89.
    View in: PubMed
    Score: 0.006
  140. Gaber N, Bero L, Woodruff TJ. The Devil they Knew: Chemical Documents Analysis of Industry Influence on PFAS Science. Ann Glob Health. 2023; 89(1):37.
    View in: PubMed
    Score: 0.006
  141. Pokorny AMJ, Bero LA, Fox P, Karikios DJ, McEwin EJ, Moynihan R, Mintzes B. Interactions between Australian cancer physicians and the pharmaceutical industry: a qualitative study. BMJ Open. 2023 05 26; 13(5):e065719.
    View in: PubMed
    Score: 0.006
  142. Bryan-Jones K, Bero LA. Tobacco industry efforts to defeat the occupational safety and health administration indoor air quality rule. Am J Public Health. 2003 Apr; 93(4):585-92.
    View in: PubMed
    Score: 0.006
  143. Langford AV, Schneider CR, Lin CC, Bero L, Collins JC, Suckling B, Gnjidic D. Patient-targeted interventions for opioid deprescribing: An overview of systematic reviews. Basic Clin Pharmacol Toxicol. 2023 Dec; 133(6):623-639.
    View in: PubMed
    Score: 0.006
  144. Hong MK, Bero LA. How the tobacco industry responded to an influential study of the health effects of secondhand smoke. BMJ. 2002 Dec 14; 325(7377):1413-6.
    View in: PubMed
    Score: 0.006
  145. Pega F, Momen NC, Bero L, Whaley P. Towards a framework for systematic reviews of the prevalence of exposure to environmental and occupational risk factors. Environ Health. 2022 07 06; 21(1):64.
    View in: PubMed
    Score: 0.006
  146. Morrow RL, Mintzes B, Souverein PC, Hallgreen CE, Ahmed B, Roughead EE, De Bruin ML, Kristiansen SB, Lexchin J, Kemp-Casey A, Sketris I, Mangin D, Pearson SA, Puil L, Lopert R, Bero L, Gnjidic D, Sarpatwari A, Dormuth CR. Hydroxyzine Initiation Following Drug Safety Advisories on Cardiac Arrhythmias in the UK and Canada: A Longitudinal Cohort Study. Drug Saf. 2022 06; 45(6):623-638.
    View in: PubMed
    Score: 0.006
  147. Pokorny AMJ, Moynihan R, Fox P, Karikios DJ, Bero LA, Mintzes BJ. Australian Cancer Physicians and the Pharmaceutical Industry: A Survey of Attitudes and Interactions. JCO Oncol Pract. 2022 07; 18(7):e1154-e1163.
    View in: PubMed
    Score: 0.006
  148. Joosse IR, Tordrup D, Bero L, Mantel-Teeuwisse AK, van den Ham HA. A critical review of methodologies used in pharmaceutical pricing policy analyses. Health Policy. 2023 Aug; 134:104576.
    View in: PubMed
    Score: 0.006
  149. Ober M, Shohara R, Rennie D, Yank V, Bero LA. The Criticism Management System for the Cochrane Library. Eval Health Prof. 2002 Mar; 25(1):98-115.
    View in: PubMed
    Score: 0.006
  150. Malone RE, Wenger LD, Bero LA. High school journalists' perspectives on tobacco. J Health Commun. 2002 Mar-Apr; 7(2):139-56.
    View in: PubMed
    Score: 0.006
  151. Pega F, Momen NC, Gagliardi D, Bero LA, Boccuni F, Chartres N, Descatha A, Dzhambov AM, Godderis L, Loney T, Mandrioli D, Modenese A, van der Molen HF, Morgan RL, Neupane S, Pachito D, Paulo MS, Prakash KC, Scheepers PTJ, Teixeira L, Tenkate T, Woodruff TJ, Norris SL. Assessing the quality of evidence in studies estimating prevalence of exposure to occupational risk factors: The QoE-SPEO approach applied in the systematic reviews from the WHO/ILO Joint Estimates of the Work-related burden of disease and Injury. Environ Int. 2022 03; 161:107136.
    View in: PubMed
    Score: 0.006
  152. Schotland MS, Bero LA. Evaluating public commentary and scientific evidence submitted in the development of a risk assessment. Risk Anal. 2002 Feb; 22(1):131-40.
    View in: PubMed
    Score: 0.006
  153. Morrow RL, Mintzes B, Souverein PC, De Bruin ML, Roughead EE, Lexchin J, Kemp-Casey A, Puil L, Sketris I, Mangin D, Hallgreen CE, Pearson SA, Lopert R, Bero L, Ofori-Asenso R, Gnjidic D, Sarpatwari A, Perry LT, Dormuth CR. Influence of drug safety advisories on drug utilisation: an international interrupted time series and meta-analysis. BMJ Qual Saf. 2022 03; 31(3):179-190.
    View in: PubMed
    Score: 0.006
  154. Korevaar E, Karahalios A, Turner SL, Forbes AB, Taljaard M, Cheng AC, Grimshaw JM, Bero L, McKenzie JE. Methodological systematic review recommends improvements to conduct and reporting when meta-analyzing interrupted time series studies. J Clin Epidemiol. 2022 05; 145:55-69.
    View in: PubMed
    Score: 0.006
  155. Bero LA, Montini T, Bryan-Jones K, Mangurian C. Science in regulatory policy making: case studies in the development of workplace smoking restrictions. Tob Control. 2001 Dec; 10(4):329-36.
    View in: PubMed
    Score: 0.006
  156. Kanukula R, McKenzie JE, Bero L, Dai Z, McDonald S, Kroeger CM, Korevaar E, Page MJ. Methods used to select results to include in meta-analyses of nutrition research: A meta-research study. J Clin Epidemiol. 2022 02; 142:171-183.
    View in: PubMed
    Score: 0.005
  157. Langford AV, Gnjidic D, Lin CC, Bero L, Blyth F, Penm J, Schneider CR. "The lesser of two evils": a framework analysis of consumers' perspectives on opioid deprescribing and the development of opioid deprescribing guidelines. Pain. 2021 11 01; 162(11):2686-2692.
    View in: PubMed
    Score: 0.005
  158. Pokorny AMJ, Bero LA, Moynihan R, Mintzes BJ. Industry payments to Australian medical oncologists and clinical haematologists: a cross-sectional analysis of publicly available disclosures. Intern Med J. 2021 Nov; 51(11):1816-1824.
    View in: PubMed
    Score: 0.005
  159. Helfer B, Leonardi-Bee J, Mundell A, Parr C, Ierodiakonou D, Garcia-Larsen V, Kroeger CM, Dai Z, Man A, Jobson J, Dewji F, Kunc M, Bero L, Boyle RJ. Conduct and reporting of formula milk trials: systematic review. BMJ. 2021 10 13; 375:n2202.
    View in: PubMed
    Score: 0.005
  160. Pokorny AMJ, Fabbri A, Bero LA, Moynihan R, Mintzes BJ. Interactions with the pharmaceutical industry and the practice, knowledge and beliefs of medical oncologists and clinical haematologists: a systematic review. Br J Cancer. 2022 01; 126(1):144-161.
    View in: PubMed
    Score: 0.005
  161. Montini T, Bero LA. Policy makers' perspectives on tobacco control advocates' roles in regulation development. Tob Control. 2001 Sep; 10(3):218-24.
    View in: PubMed
    Score: 0.005
  162. Wenger LD, Malone RE, George A, Bero LA. Cigar magazines: using tobacco to sell a lifestyle. Tob Control. 2001 Sep; 10(3):279-84.
    View in: PubMed
    Score: 0.005
  163. Fabbri A, Nejstgaard CH, Grundy Q, Bero L, Dunn AG, Mohammad A, Mintzes B. Association Between Conflicts of Interest and Authors' Positions on Harms of Varenicline: a Cross-Sectional Analysis. J Gen Intern Med. 2022 02; 37(2):290-297.
    View in: PubMed
    Score: 0.005
  164. Lexchin J, Bero LA, Davis C, Gagnon MA. Achieving greater independence from commercial influence in research. BMJ. 2021 03 09; 372:n370.
    View in: PubMed
    Score: 0.005
  165. Wenger L, Malone R, Bero L. The cigar revival and the popular press: a content analysis, 1987-1997. Am J Public Health. 2001 Feb; 91(2):288-91.
    View in: PubMed
    Score: 0.005
  166. Nejstgaard CH, Bero L, Hr?bjartsson A, J?rgensen AW, J?rgensen KJ, Le M, Lundh A. Association between conflicts of interest and favourable recommendations in clinical guidelines, advisory committee reports, opinion pieces, and narrative reviews: systematic review. BMJ. 2020 12 09; 371:m4234.
    View in: PubMed
    Score: 0.005
  167. Nejstgaard CH, Bero L, Hr?bjartsson A, J?rgensen AW, J?rgensen KJ, Le M, Lundh A. Conflicts of interest in clinical guidelines, advisory committee reports, opinion pieces, and narrative reviews: associations with recommendations. Cochrane Database Syst Rev. 2020 12 08; 12:MR000040.
    View in: PubMed
    Score: 0.005
  168. Wang Z, Bero L, Grundy Q. Understanding professional stakeholders' active resistance to guideline implementation: The case of Canadian breast screening guidelines. Soc Sci Med. 2021 01; 269:113586.
    View in: PubMed
    Score: 0.005
  169. Mangurian CV, Bero LA. Lessons learned from the tobacco industry's efforts to prevent the passage of a workplace smoking regulation. Am J Public Health. 2000 Dec; 90(12):1926-30.
    View in: PubMed
    Score: 0.005
  170. Soares-Weiser K, Lasserson T, Jorgensen KJ, Woloshin S, Bero L, Brown MD, Fischhoff B. Policy makers must act on incomplete evidence in responding to COVID-19. Cochrane Database Syst Rev. 2020 11 20; 11:ED000149.
    View in: PubMed
    Score: 0.005
  171. Turner SL, Karahalios A, Forbes AB, Taljaard M, Grimshaw JM, Korevaar E, Cheng AC, Bero L, McKenzie JE. Creating effective interrupted time series graphs: Review and recommendations. Res Synth Methods. 2021 Jan; 12(1):106-117.
    View in: PubMed
    Score: 0.005
  172. Mialon M, Vandevijvere S, Carriedo-Lutzenkirchen A, Bero L, Gomes F, Petticrew M, McKee M, Stuckler D, Sacks G. Mechanisms for addressing and managing the influence of corporations on public health policy, research and practice: a scoping review. BMJ Open. 2020 07 19; 10(7):e034082.
    View in: PubMed
    Score: 0.005
  173. Moynihan R, Macdonald H, Bero L, Godlee F. Commercial influence and covid-19. BMJ. 2020 06 24; 369:m2456.
    View in: PubMed
    Score: 0.005
  174. Turner K, Carboni-Jim?nez A, Benea C, Elder K, Levis B, Boruff J, Roseman M, Bero L, Lexchin J, Turner EH, Benedetti A, Thombs BD. Reporting of drug trial funding sources and author financial conflicts of interest in Cochrane and non-Cochrane meta-analyses: a cross-sectional study. BMJ Open. 2020 05 11; 10(5):e035633.
    View in: PubMed
    Score: 0.005
  175. Malone RE, Bero LA. Cigars, youth, and the Internet link. Am J Public Health. 2000 May; 90(5):790-2.
    View in: PubMed
    Score: 0.005
  176. Benea C, Turner KA, Roseman M, Bero LA, Lexchin J, Turner EH, Thombs BD. Reporting of financial conflicts of interest in meta-analyses of drug trials published in high-impact medical journals: comparison of results from 2017 to 2018 and 2009. Syst Rev. 2020 04 08; 9(1):77.
    View in: PubMed
    Score: 0.005
  177. Langford AV, Gnjidic D, Lin CC, Bero L, Penm J, Blyth FM, Schneider CR. Challenges of opioid deprescribing and factors to be considered in the development of opioid deprescribing guidelines: a qualitative analysis. BMJ Qual Saf. 2021 02; 30(2):133-140.
    View in: PubMed
    Score: 0.005
  178. Turner SL, Karahalios A, Forbes AB, Taljaard M, Grimshaw JM, Cheng AC, Bero L, McKenzie JE. Design characteristics and statistical methods used in interrupted time series studies evaluating public health interventions: a review. J Clin Epidemiol. 2020 06; 122:1-11.
    View in: PubMed
    Score: 0.005
  179. Korevaar E, Karahalios A, Forbes AB, Turner SL, McDonald S, Taljaard M, Grimshaw JM, Cheng AC, Bero L, McKenzie JE. Methods used to meta-analyse results from interrupted time series studies: A methodological systematic review protocol. F1000Res. 2020; 9:110.
    View in: PubMed
    Score: 0.005
  180. Freemantle N, Harvey EL, Wolf F, Grimshaw JM, Grilli R, Bero LA. Printed educational materials: effects on professional practice and health care outcomes. Cochrane Database Syst Rev. 2000; (2):CD000172.
    View in: PubMed
    Score: 0.005
  181. Bero LA, Mays NB, Barjesteh K, Bond C. Expanding the roles of outpatient pharmacists: effects on health services utilisation, costs, and patient outcomes. Cochrane Database Syst Rev. 2000; (2):CD000336.
    View in: PubMed
    Score: 0.005
  182. Samet JM, Chiu WA, Cogliano V, Jinot J, Kriebel D, Lunn RM, Beland FA, Bero L, Browne P, Fritschi L, Kanno J, Lachenmeier DW, Lan Q, Lasfargues G, Le Curieux F, Peters S, Shubat P, Sone H, White MC, Williamson J, Yakubovskaya M, Siemiatycki J, White PA, Guyton KZ, Schubauer-Berigan MK, Hall AL, Grosse Y, Bouvard V, Benbrahim-Tallaa L, El Ghissassi F, Lauby-Secretan B, Armstrong B, Saracci R, Zavadil J, Straif K, Wild CP. The IARC Monographs: Updated Procedures for Modern and Transparent Evidence Synthesis in Cancer Hazard Identification. J Natl Cancer Inst. 2020 01 01; 112(1):30-37.
    View in: PubMed
    Score: 0.005
  183. Pega F, Norris SL, Backes C, Bero LA, Descatha A, Gagliardi D, Godderis L, Loney T, Modenese A, Morgan RL, Pachito D, Paulo MBS, Scheepers PTJ, Schl?nssen V, Sgargi D, Silbergeld EK, S?rensen K, Sutton P, Tenkate T, Torre?o Corr?a da Silva D, Ujita Y, van Deventer E, Woodruff TJ, Mandrioli D. RoB-SPEO: A tool for assessing risk of bias in studies estimating the prevalence of exposure to occupational risk factors from the WHO/ILO Joint Estimates of the Work-related Burden of Disease and Injury. Environ Int. 2020 02; 135:105039.
    View in: PubMed
    Score: 0.005
  184. Johansson M, Bero L, Bonfill X, Bruschettini M, Garner S, Glenton C, Harris R, J?rgensen KJ, Levinson W, Lotfi T, Montori V, Meng DM, Sch?nemann H, Vaz Carneiro A, Woloshin S, Moynihan R. Cochrane Sustainable Healthcare: evidence for action on too much medicine. Cochrane Database Syst Rev. 2019 12 06; 12:ED000143.
    View in: PubMed
    Score: 0.005
  185. Moynihan R, Bero L, Hill S, Johansson M, Lexchin J, Macdonald H, Mintzes B, Pearson C, Rodwin MA, Stavdal A, Stegenga J, Thombs BD, Thornton H, Vandvik PO, Wieseler B, Godlee F. Pathways to independence: towards producing and using trustworthy evidence. BMJ. 2019 Dec 03; 367:l6576.
    View in: PubMed
    Score: 0.005
  186. Urato AC, Abi-Jaoude E, Abramson J, Alter H, Andrew LB, Antonuccio D, Bero L, Biron P, Boylan LS, Braillon A, Brophy JM, Brownlee S, Cassels A, Cook-Deegan R, Cosgrove L, De Fiore L, Deyo RA, Elshaug A, Farquhar C, Fatovich DM, Fingerman E, G?rvas J, G?tzsche PC, Gracia R, Heath I, Himmelstein DU, Hoffman JR, J?rvinen T, Jureidini J, Kotaska A, Kuehlein T, Lenzer J, Levenstein S, Lexchin J, Mintzes B, Naudet F, Niquette M, Orellana Navarrete LP, Pearson CA, Rail G, Roberts R, Shah N, Sharav V, Siwek J, Topolski S, Tsai AC. National Partnership for Maternal Safety: Consensus Bundle on Venous Thromboembolism. Obstet Gynecol. 2019 11; 134(5):1115-1117.
    View in: PubMed
    Score: 0.005
  187. Grundy Q, Chiu K, Held F, Continella A, Bero L, Holz R. Data sharing practices of medicines related apps and the mobile ecosystem: traffic, content, and network analysis. BMJ. 2019 03 20; 364:l920.
    View in: PubMed
    Score: 0.005
  188. Parker L, Bero L, Gillies D, Raven M, Grundy Q. The "Hot Potato" of Mental Health App Regulation: A Critical Case Study of the Australian Policy Arena. Int J Health Policy Manag. 2019 03 01; 8(3):168-176.
    View in: PubMed
    Score: 0.005
  189. Turner SL, Karahalios A, Forbes AB, Taljaard M, Grimshaw JM, Cheng AC, Bero L, McKenzie JE. Design characteristics and statistical methods used in interrupted time series studies evaluating public health interventions: protocol for a review. BMJ Open. 2019 01 28; 9(1):e024096.
    View in: PubMed
    Score: 0.005
  190. Kennedy GE, Bero LA. Print media coverage of research on passive smoking. Tob Control. 1999; 8(3):254-60.
    View in: PubMed
    Score: 0.005
  191. Chartres N, Bero LA, Norris SL. A review of methods used for hazard identification and risk assessment of environmental hazards. Environ Int. 2019 02; 123:231-239.
    View in: PubMed
    Score: 0.004
  192. Rasmussen K, Bero L, Redberg R, G?tzsche PC, Lundh A. Collaboration between academics and industry in clinical trials: cross sectional study of publications and survey of lead academic authors. BMJ. 2018 Oct 03; 363:k3654.
    View in: PubMed
    Score: 0.004
  193. van der Eijk Y, Bero LA, Malone RE. Philip Morris International-funded 'Foundation for a Smoke-Free World': analysing its claims of independence. Tob Control. 2019 11; 28(6):712-718.
    View in: PubMed
    Score: 0.004
  194. Misakian AL, Bero LA. Publication bias and research on passive smoking: comparison of published and unpublished studies. JAMA. 1998 Jul 15; 280(3):250-3.
    View in: PubMed
    Score: 0.004
  195. Parker L, Bero L, Gillies D, Raven M, Mintzes B, Jureidini J, Grundy Q. Mental Health Messages in Prominent Mental Health Apps. Ann Fam Med. 2018 07; 16(4):338-342.
    View in: PubMed
    Score: 0.004
  196. Barnes DE, Bero LA. Why review articles on the health effects of passive smoking reach different conclusions. JAMA. 1998 May 20; 279(19):1566-70.
    View in: PubMed
    Score: 0.004
  197. Mahmic-Kaknjo M, Jelicic-Kadic A, Utrobicic A, Chan K, Bero L, Maru?ic A. Essential medicines availability is still suboptimal in many countries: a scoping review. J Clin Epidemiol. 2018 06; 98:41-52.
    View in: PubMed
    Score: 0.004
  198. Bero LA, Jadad AR. How consumers and policymakers can use systematic reviews for decision making. Ann Intern Med. 1997 Jul 01; 127(1):37-42.
    View in: PubMed
    Score: 0.004
  199. Walker J, Chaar BB, Vera N, Pillai AS, Lim JS, Bero L, Moles RJ. Medicine shortages in Fiji: A qualitative exploration of stakeholders' views. PLoS One. 2017; 12(6):e0178429.
    View in: PubMed
    Score: 0.004
  200. Barnes DE, Bero LA. Scientific quality of original research articles on environmental tobacco smoke. Tob Control. 1997; 6(1):19-26.
    View in: PubMed
    Score: 0.004
  201. Lawrence M, Naude C, Armstrong R, Bero L, Covic N, Durao S, Ghersi D, Macdonald G, MacLehose H, Margetts B, Tovey D, Volmink J, Young T. A call to action to reshape evidence synthesis and use for nutrition policy. Cochrane Database Syst Rev. 2016 Nov 21; 11:ED000118.
    View in: PubMed
    Score: 0.004
  202. Stryer D, Bero LA. Characteristics of materials distributed by drug companies. An evaluation of appropriateness. J Gen Intern Med. 1996 Oct; 11(10):575-83.
    View in: PubMed
    Score: 0.004
  203. Vandenberg LN, ?gerstrand M, Beronius A, Beausoleil C, Bergman ?, Bero LA, Bornehag CG, Boyer CS, Cooper GS, Cotgreave I, Gee D, Grandjean P, Guyton KZ, Hass U, Heindel JJ, Jobling S, Kidd KA, Kortenkamp A, Macleod MR, Martin OV, Norinder U, Scheringer M, Thayer KA, Toppari J, Whaley P, Woodruff TJ, Rud?n C. A proposed framework for the systematic review and integrated assessment (SYRINA) of endocrine disrupting chemicals. Environ Health. 2016 07 14; 15(1):74.
    View in: PubMed
    Score: 0.004
  204. Johnson PI, Koustas E, Vesterinen HM, Sutton P, Atchley DS, Kim AN, Campbell M, Donald JM, Sen S, Bero L, Zeise L, Woodruff TJ. Application of the Navigation Guide systematic review methodology to the evidence for developmental and reproductive toxicity of triclosan. Environ Int. 2016 Jul-Aug; 92-93:716-28.
    View in: PubMed
    Score: 0.004
  205. Grundy Q, Bero LA, Malone RE. Marketing and the Most Trusted Profession: The Invisible Interactions Between Registered Nurses and Industry. Ann Intern Med. 2016 06 07; 164(11):733-9.
    View in: PubMed
    Score: 0.004
  206. Cho MK, Bero LA. The quality of drug studies published in symposium proceedings. Ann Intern Med. 1996 Mar 01; 124(5):485-9.
    View in: PubMed
    Score: 0.004
  207. Stryer DB, Lurie P, Bero LA. Dear doctor ... regarding calcium channel blockers. JAMA. 1996 Feb 21; 275(7):517-9.
    View in: PubMed
    Score: 0.004
  208. Phillips KA, Bero LA. Improving the use of information in medical effectiveness research. Int J Qual Health Care. 1996 Feb; 8(1):21-30.
    View in: PubMed
    Score: 0.004
  209. Morgan RL, Thayer KA, Bero L, Bruce N, Falck-Ytter Y, Ghersi D, Guyatt G, Hooijmans C, Langendam M, Mandrioli D, Mustafa RA, Rehfuess EA, Rooney AA, Shea B, Silbergeld EK, Sutton P, Wolfe MS, Woodruff TJ, Verbeek JH, Holloway AC, Santesso N, Sch?nemann HJ. GRADE: Assessing the quality of evidence in environmental and occupational health. Environ Int. 2016 Jul-Aug; 92-93:611-6.
    View in: PubMed
    Score: 0.004
  210. Barnes DE, Bero LA. Industry-funded research and conflict of interest: an analysis of research sponsored by the tobacco industry through the Center for Indoor Air Research. J Health Polit Policy Law. 1996; 21(3):515-42.
    View in: PubMed
    Score: 0.004
  211. Elliott JH, Grimshaw J, Altman R, Bero L, Goodman SN, Henry D, Macleod M, Tovey D, Tugwell P, White H, Sim I. Informatics: Make sense of health data. Nature. 2015 Nov 05; 527(7576):31-2.
    View in: PubMed
    Score: 0.004
  212. Alexander PE, Gionfriddo MR, Li SA, Bero L, Stoltzfus RJ, Neumann I, Brito JP, Djulbegovic B, Montori VM, Norris SL, Sch?nemann HJ, Thabane L, Guyatt GH. A number of factors explain why WHO guideline developers make strong recommendations inconsistent with GRADE guidance. J Clin Epidemiol. 2016 Feb; 70:111-22.
    View in: PubMed
    Score: 0.004
  213. Bero L, Barnes DE, Hanauer P, Slade J, Glantz SA. Lawyer control of the tobacco industry's external research program. The Brown and Williamson documents. JAMA. 1995 Jul 19; 274(3):241-7.
    View in: PubMed
    Score: 0.004
  214. Chang L, Dhruva SS, Chu J, Bero LA, Redberg RF. Selective reporting in trials of high risk cardiovascular devices: cross sectional comparison between premarket approval summaries and published reports. BMJ. 2015 Jun 10; 350:h2613.
    View in: PubMed
    Score: 0.004
  215. Moynihan R, Nickel B, Hersch J, Beller E, Doust J, Compton S, Barratt A, Bero L, McCaffery K. Public Opinions about Overdiagnosis: A National Community Survey. PLoS One. 2015; 10(5):e0125165.
    View in: PubMed
    Score: 0.004
  216. Chiu Y, Bero L, Hessol NA, Lexchin J, Harrington C. A literature review of clinical outcomes associated with antipsychotic medication use in North American nursing home residents. Health Policy. 2015 Jun; 119(6):802-13.
    View in: PubMed
    Score: 0.003
  217. Hill SR, Bero L, McColl G, Roughead E. Expensive medicines: ensuring objective appraisal and equitable access. Bull World Health Organ. 2015 Jan 01; 93(1):4.
    View in: PubMed
    Score: 0.003
  218. Alexander PE, Brito JP, Neumann I, Gionfriddo MR, Bero L, Djulbegovic B, Stoltzfus R, Montori VM, Norris SL, Sch?nemann HJ, Guyatt GH. World Health Organization strong recommendations based on low-quality evidence (study quality) are frequent and often inconsistent with GRADE guidance. J Clin Epidemiol. 2016 Apr; 72:98-106.
    View in: PubMed
    Score: 0.003
  219. Mahady SE, Schlub T, Bero L, Moher D, Tovey D, George J, Craig JC. Side effects are incompletely reported among systematic reviews in gastroenterology. J Clin Epidemiol. 2015 Feb; 68(2):144-53.
    View in: PubMed
    Score: 0.003
  220. Coralic Z, Kanzaria HK, Bero L, Stein J. Staff perceptions of an on-site clinical pharmacist program in an academic emergency department after one year. West J Emerg Med. 2014 Mar; 15(2):205-10.
    View in: PubMed
    Score: 0.003
  221. Alexander PE, Bero L, Montori VM, Brito JP, Stoltzfus R, Djulbegovic B, Neumann I, Rave S, Guyatt G. World Health Organization recommendations are often strong based on low confidence in effect estimates. J Clin Epidemiol. 2014 Jun; 67(6):629-34.
    View in: PubMed
    Score: 0.003
  222. Neltner TG, Alger HM, O'Reilly JT, Krimsky S, Bero LA, Maffini MV. Conflicts of interest in approvals of additives to food determined to be generally recognized as safe: out of balance. JAMA Intern Med. 2013 Dec 9-23; 173(22):2032-6.
    View in: PubMed
    Score: 0.003
  223. Grundy Q, Bero L, Malone R. Interactions between non-physician clinicians and industry: a systematic review. PLoS Med. 2013 Nov; 10(11):e1001561.
    View in: PubMed
    Score: 0.003
  224. Moynihan RN, Cooke GP, Doust JA, Bero L, Hill S, Glasziou PP. Expanding disease definitions in guidelines and expert panel ties to industry: a cross-sectional study of common conditions in the United States. PLoS Med. 2013 Aug; 10(8):e1001500.
    View in: PubMed
    Score: 0.003
  225. Schroll JB, Bero L, G?tzsche PC. Searching for unpublished data for Cochrane reviews: cross sectional study. BMJ. 2013 Apr 23; 346:f2231.
    View in: PubMed
    Score: 0.003
  226. Conway J, Bero L, Ondari C, Wasan KM. Review of the quality of pediatric medications in developing countries. J Pharm Sci. 2013 May; 102(5):1419-33.
    View in: PubMed
    Score: 0.003
  227. Roseman M, Turner EH, Lexchin J, Coyne JC, Bero LA, Thombs BD. Reporting of conflicts of interest from drug trials in Cochrane reviews: cross sectional study. BMJ. 2012 Aug 16; 345:e5155.
    View in: PubMed
    Score: 0.003
  228. Norris SL, Burda BU, Holmer HK, Ogden LA, Fu R, Bero L, Sch?nemann H, Deyo R. Author's specialty and conflicts of interest contribute to conflicting guidelines for screening mammography. J Clin Epidemiol. 2012 Jul; 65(7):725-33.
    View in: PubMed
    Score: 0.003
  229. Bero LA, Lipton HL, Bird JA. Characterization of geriatric drug-related hospital readmissions. Med Care. 1991 Oct; 29(10):989-1003.
    View in: PubMed
    Score: 0.003
  230. Dhruva SS, Bero LA, Redberg RF. Gender bias in studies for Food and Drug Administration premarket approval of cardiovascular devices. Circ Cardiovasc Qual Outcomes. 2011 Mar; 4(2):165-71.
    View in: PubMed
    Score: 0.003
  231. Ridge AL, Bero LA, Hill SR. Identifying barriers to the availability and use of Magnesium Sulphate Injection in resource poor countries: a case study in Zambia. BMC Health Serv Res. 2010 Dec 16; 10:340.
    View in: PubMed
    Score: 0.003
  232. Chen CE, Dhruva SS, Bero LA, Redberg RF. Inclusion of training patients in US Food and Drug Administration premarket approval cardiovascular device studies. Arch Intern Med. 2011 Mar 28; 171(6):534-9.
    View in: PubMed
    Score: 0.003
  233. Cataldo JK, Bero LA, Malone RE. "A delicate diplomatic situation": tobacco industry efforts to gain control of the Framingham Study. J Clin Epidemiol. 2010 Aug; 63(8):841-53.
    View in: PubMed
    Score: 0.003
  234. Robertson J, Walkom E, Moynihan R, Bero L, Henry D. Pharmaceutical industry funding of educational events for pharmacists in Australia: an analysis of data from the first 6 months of a mandatory disclosure programme. Int J Pharm Pract. 2010 Apr; 18(2):88-92.
    View in: PubMed
    Score: 0.002
  235. Dhruva SS, Bero LA, Redberg RF. Strength of study evidence examined by the FDA in premarket approval of cardiovascular devices. JAMA. 2009 Dec 23; 302(24):2679-85.
    View in: PubMed
    Score: 0.002
  236. Vedula SS, Bero L, Scherer RW, Dickersin K. Outcome reporting in industry-sponsored trials of gabapentin for off-label use. N Engl J Med. 2009 Nov 12; 361(20):1963-71.
    View in: PubMed
    Score: 0.002
  237. Robertson J, Moynihan R, Walkom E, Bero L, Henry D. Mandatory disclosure of pharmaceutical industry-funded events for health professionals. PLoS Med. 2009 Nov; 6(11):e1000128.
    View in: PubMed
    Score: 0.002
  238. Grimshaw J, McAuley LM, Bero LA, Grilli R, Oxman AD, Ramsay C, Vale L, Zwarenstein M. Systematic reviews of the effectiveness of quality improvement strategies and programmes. Qual Saf Health Care. 2003 Aug; 12(4):298-303.
    View in: PubMed
    Score: 0.002
  239. Rochon PA, Bero LA, Bay AM, Gold JL, Dergal JM, Binns MA, Streiner DL, Gurwitz JH. Comparison of review articles published in peer-reviewed and throwaway journals. JAMA. 2002 Jun 05; 287(21):2853-6.
    View in: PubMed
    Score: 0.001
  240. Anderson J, Baum M, Bero LA, Chalmers I, Chapman S, Deary IJ, Ebrahim S, Evans M, Farrell M, Greaves D, Higginson I, Hippisley-Cox J, James B, McKenzie H, Macaulay AC, Rabow M, Smyth RL, Stores G, Wolpert L. Music to be born to, music to die to. BMJ. 2000 Dec 23-30; 321(7276):1577-9.
    View in: PubMed
    Score: 0.001
  241. Moynihan R, Bero L, Ross-Degnan D, Henry D, Lee K, Watkins J, Mah C, Soumerai SB. Coverage by the news media of the benefits and risks of medications. N Engl J Med. 2000 Jun 01; 342(22):1645-50.
    View in: PubMed
    Score: 0.001
  242. Beney J, Bero LA, Bond C. Expanding the roles of outpatient pharmacists: effects on health services utilisation, costs, and patient outcomes. Cochrane Database Syst Rev. 2000; (3):CD000336.
    View in: PubMed
    Score: 0.001
  243. Granados A, Jonsson E, Banta HD, Bero L, Bonair A, Cochet C, Freemantle N, Grilli R, Grimshaw J, Harvey E, Levi R, Marshall D, Oxman A, Pasart L, R?is?nen V, Rius E, Espinas JA. EUR-ASSESS Project Subgroup Report on Dissemination and Impact. Int J Technol Assess Health Care. 1997; 13(2):220-86.
    View in: PubMed
    Score: 0.001
  244. Gill PS, Freemantle N, Bero L, Haaijer-Ruskamp F, Markela M, Barjesteh KP. GPs' prescribing behaviour may be affected by drug promotion. BMJ. 1996 Aug 10; 313(7053):367.
    View in: PubMed
    Score: 0.001
  245. de Vries TP, Henning RH, Hogerzeil HV, Bapna JS, Bero L, Kafle KK, Mabadeje Af, Santoso B, Smith AJ. Impact of a short course in pharmacotherapy for undergraduate medical students: an international randomised controlled study. Lancet. 1995 Dec 02; 346(8988):1454-7.
    View in: PubMed
    Score: 0.001
  246. Hornbein T, Bero L, Rennie D. The publication of commercially supported supplements statement. Anesth Analg. 1995 Oct; 81(4):887-8; author reply 888-9.
    View in: PubMed
    Score: 0.001
  247. Glantz SA, Barnes DE, Bero L, Hanauer P, Slade J. Looking through a keyhole at the tobacco industry. The Brown and Williamson documents. JAMA. 1995 Jul 19; 274(3):219-24.
    View in: PubMed
    Score: 0.001
  248. Slade J, Bero LA, Hanauer P, Barnes DE, Glantz SA. Nicotine and addiction. The Brown and Williamson documents. JAMA. 1995 Jul 19; 274(3):225-33.
    View in: PubMed
    Score: 0.001
  249. Hanauer P, Slade J, Barnes DE, Bero L, Glantz SA. Lawyer control of internal scientific research to protect against products liability lawsuits. The Brown and Williamson documents. JAMA. 1995 Jul 19; 274(3):234-40.
    View in: PubMed
    Score: 0.001
  250. Barnes DE, Hanauer P, Slade J, Bero LA, Glantz SA. Environmental tobacco smoke. The Brown and Williamson documents. JAMA. 1995 Jul 19; 274(3):248-53.
    View in: PubMed
    Score: 0.001
  251. Kearney TE, Olson KR, Bero LA, Heard SE, Blanc PD. Health care cost effects of public use of a regional poison control center. West J Med. 1995 Jun; 162(6):499-504.
    View in: PubMed
    Score: 0.001
  252. Lipton HL, Bird JA, Bero LA, McPhee SJ. Assessing the appropriateness of physician prescribing for geriatric outpatients. Development and testing of an instrument. J Pharm Technol. 1993 May-Jun; 9(3):107-13.
    View in: PubMed
    Score: 0.001
  253. Lipton HL, Bero LA, Bird JA, McPhee SJ. The impact of clinical pharmacists' consultations on physicians' geriatric drug prescribing. A randomized controlled trial. Med Care. 1992 Jul; 30(7):646-58.
    View in: PubMed
    Score: 0.001
  254. Braude MC, Szeto HH, Kuhn CM, Bero L, Ignar D, Field E, Lurie S, Chasnoff IJ, Mendelson JH, Zuckerman B, et al. Perinatal effects of drugs of abuse. Fed Proc. 1987 May 15; 46(7):2446-53.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2024 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)